Dermata Therapeutics, Inc. Common Stock (DRMA) is a publicly traded Healthcare sector company. As of May 21, 2026, DRMA trades at $1.23 with a market cap of $4.83M and a P/E ratio of -0.15. DRMA moved +0.00% today. Year to date, DRMA is -43.18%; over the trailing twelve months it is -84.53%. Its 52-week range spans $1.10 to $23.70. Analyst consensus is buy with an average price target of $4.00. Rallies surfaces DRMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own DRMA include Two Sigma and Citadel Advisors. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Dermata Therapeutics, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $1.23 |
| Market Cap | $4.83M |
| P/E Ratio | -0.15 |
| EPS | $-8.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $23.70 |
| 52-Week Low | $1.10 |
| Volume | 158 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-7.56M |
| Gross Margin | 0.00% |
1 analysts cover DRMA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.00.